1. Treatment with lixisenatide in type 2 diabetic (DM2) patients was shown to result in rates of coronary events similar to those of placebo. 2. Treatment with lixisenatide in DM2 patients offers mild clinical and metabolic benefits compared to placebo, including weight loss and lowered HbA1C. Evidence Rating: 1 (Excellent) Study Rundown: Patients with DM2
↧